More on Regeneron/Avastin: Though the FDA's decision is a positive for Regeneron (REGN -2.1%),...

|About: Regeneron Pharmaceuticals, ... (REGN)|By:, SA News Editor

More on Regeneron/Avastin: Though the FDA's decision is a positive for Regeneron (REGN -2.1%), which offers its costlier Eylea drug as an alternative to Roche's (RHHBY.PK +0.9%) Avastin, many saw the decision coming, given prior news (I, II). In addition, investors may be focusing on the FDA's remarks (.pdf) about Avastin possibly being reapproved in the future, following new trials.